Search research articles
Contact Us
Filters
Showing results (171-180 of 183) with videos related to
Page
of 19
Sort By:
The New England Journal of Medicine
|
October 1, 2010
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Oncotarget
|
February 22, 2018
MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group
Risa Niemas-Teshiba, Ryosuke Matsuno, Larry L Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2022
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group
Ami V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, et al.
Journal of the National Cancer Institute
|
July 30, 2011
ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux
Michelle J Henderson, Michelle Haber, Antonio Porro, et al.
Pediatric Blood & Cancer
|
June 30, 2012
Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee
Rie Suganuma, Larry L Wang, Hideki Sano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2022
Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study
Danielle Novetsky Friedman, Pamela J Goodman, Wendy M Leisenring, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2025
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group
Florette K Hazard, Angus M S Toland, Serena Y Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2017
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Amy K Erbe, Wei Wang, Lakeesha Carmichael, et al.
Journal of the National Cancer Institute
|
March 9, 2024
Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study
Danielle Novetsky Friedman, Pamela J Goodman, Wendy M Leisenring, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2018
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Steven G DuBois, Yael P Mosse, Elizabeth Fox, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 183) with videos related to
Sort By:
Page
of 19
The New England Journal of Medicine
|
October 1, 2010
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Oncotarget
|
February 22, 2018
MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group
Risa Niemas-Teshiba, Ryosuke Matsuno, Larry L Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2022
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group
Ami V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, et al.
Journal of the National Cancer Institute
|
July 30, 2011
ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux
Michelle J Henderson, Michelle Haber, Antonio Porro, et al.
Pediatric Blood & Cancer
|
June 30, 2012
Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee
Rie Suganuma, Larry L Wang, Hideki Sano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2022
Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study
Danielle Novetsky Friedman, Pamela J Goodman, Wendy M Leisenring, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2025
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group
Florette K Hazard, Angus M S Toland, Serena Y Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2017
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Amy K Erbe, Wei Wang, Lakeesha Carmichael, et al.
Journal of the National Cancer Institute
|
March 9, 2024
Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study
Danielle Novetsky Friedman, Pamela J Goodman, Wendy M Leisenring, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2018
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Steven G DuBois, Yael P Mosse, Elizabeth Fox, et al.
Page
of 19